Solubility advantage of amorphous pharmaceuticals, part 3: Is maximum solubility advantage experimentally attainable and sustainable?

Journal of Pharmaceutical Sciences

Volumn 100, Issue 10, 2011, Pages 4349-4356

  Murdande, Sharad B ^a,b   Pikal, Michael J ^a   Shanker, Ravi M ^b   Bogner, Robin H ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Amorphous; Cellulosic polymers; Crystal; Polymers; Recrystallization; Solubility; Supersaturation

Indexed keywords

AMORPHOUS DRUG; DANAZOL; DRUG; GRISEOFULVIN; HYDROXYPROPYLMETHYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE ACETATE SUCCINATE; IOPANOIC ACID; POVIDONE; UNCLASSIFIED DRUG; COLLOID; METHYLCELLULOSE;

ARTICLE; CRYSTALLIZATION; DRUG BIOAVAILABILITY; DRUG SCREENING; DRUG SOLUBILITY; DYNAMIC LIGHT SCATTERING; PHOTON CORRELATION SPECTROSCOPY; ULTRACENTRIFUGATION; ANALOGS AND DERIVATIVES; CHEMISTRY; COLLOID; COMPARATIVE STUDY; KINETICS; LIGHT; MEDICINAL CHEMISTRY; PHARMACEUTICS; PROCEDURES; RADIATION SCATTERING; SOLUBILITY;

CHEMISTRY, PHARMACEUTICAL; COLLOIDS; CRYSTALLIZATION; DANAZOL; GRISEOFULVIN; HYPROMELLOSE DERIVATIVES; IOPANOIC ACID; KINETICS; LIGHT; METHYLCELLULOSE; PHARMACEUTICAL PREPARATIONS; POVIDONE; SCATTERING, RADIATION; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; ULTRACENTRIFUGATION;

EID: 80052261018     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22643     Document Type: Article

References (32)

1. Goldberg AH, Gibaldi M, Kanig JL. 1966. Increasing dissolution rates and gastrointestinal abosorption of drugs via solid solutions. J Pharm Sci 55:487-492.
2. Leuner C, Dressman J. 2000. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 50(1):47-60.
3. Hancock BC, Parks M. 2000. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 17(4):397-404.
4. Yu L. 2001. Amorphous pharmaceutical solids: Preparation, characterization and stabilization. Adv Drug Deliv Rev 48(1):27-42.
5. Vasconcelos T, Sarmento B, Costa P. 2007. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 12(23-24):1068-1075.
6. Serajuddin ATM. 1999. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88(10):1058-1066.
7. Sethia S, Sequillante E. 2003. Solid Dispersions: Revival with greater possibilities and applications in oral drug delivery. Crit Rev Ther Drug Carrier Syst 20(2-3):215-247.
8. Murdande SB, Pikal MJ, Shanker RM, Bogner RH. 2010. Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis. J Pharm Sci 99(3):1254-1264.
9. Murdande S, Pikal M, Shanker R, Bogner R. 2010. Solubility advantage of amorphous pharmaceuticals: II. Application of quantitative thermodynamic relationships for prediction of solubility enhancement in structurally diverse insoluble pharmaceuticals. Pharm Res 27(12):2704-2714.
10. Sekiguchi K, Obi N. 1961. Absorption of eutectic mixtures. I. A comparison of the behavior of a eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem Pharm Bull 9:866-872.
11. Mayersohn M, Gibaldi M. 1966. New method of solid-state dispersion for increasing dissolution rates. J Pharm Sci 55(11):1323-1324.
12. Simonelli AP, Mehta SC, Higuchi WI. 1969. Dissolution rates of high energy polyvinylpyrrolidone (PVP)-sulfathiazole coprecipitates. J Pharm Sci 58:538-549.
13. Corrigan OI, Timoney RF, Whelan MJ. 1976. The influence of polyvinylpyrrolidone on the dissolution and bioavailability of hydrochlorothiazide. J Pharm Pharmacol 28:703-706.
14. Tantishaiyakul V, Kaewnopparat N, Ingkatawornwong S. 1999. Properties of solid dispersions of piroxicam in polyvinylpyrrolidone. Int J Pharm 181:143-151.
15. Konno H, Taylor LS. 2006. Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J Pharm Sci 95(12):2692-2705.
16. Gupta P, Kakumanu VK, Bansal AK. 2004. Stability and solubility of celecoxib-PVP amorphous dispersions: A molecular perspective. Pharm Res 21(10):1762-1769.
17. Lervolino M, Raghavan SL, Hadgraft J. 2000. Membrane penetration enhancement of ibuprofen using supersaturation. Int J Pharm 198:229-238.
18. Lervolino M, Raghavan SL, Hadgraft J. 2001. Penetration enhancement of ibuprofen from supersaturated solutions through human skin. Int J Pharm 212:131-141.
19. Simonelli AP, Mehta SC, Higuchi WI. 1970. Inhibition of sulfothiazole crystal growth by polyvinylpyrrolidone. J Pharm Sci 57:633-638.
20. Sekikawa H, Nakano M, Arita T. 1978. Inhibitory effect of polyvinylpyrrolidone on the crystallization of drugs. Chem Pharm Bull 26:118-126.
21. Nair R, Gonen R, Hoag SW. 2002. Influence of polyethylene glycol and povidone on the polymorphic transformation and solubility of carbamazepine. Int J Pharm 240:11-22.
22. Raghavan SL, Trividic A, Davis AF, Hadgraft J. 2001. Crystallization of hydrocortisone acetate: Influence of polymers. Int J Pharm 212(2):213-221.
23. Konno H, Handa T, Alonzo DE, Taylor LS. 2008. Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine. Eur J Pharm Biopharm 70(2):493-499.
24. Murdande SB, Pikal MJ, Shanker RM, Bogner RH. 2010. Aqueous solubility of crystalline and amorphous drugs: Challenges in measurement. Pharm Dev Technol 0(0):1-13.
25. Loftsson T, Fririksdóttir H, Gumundsdóttir TK. 1996. The effect of water-soluble polymers on aqueous solubility of drugs. Int J Pharm 127(2):293-296.
26. Usui F, Maeda K, Kusai A, Nishimura K, Keiji Y. 1997. Inhibitory effects of water-soluble polymers on precipitation of RS-8359. Int J Pharm 154(1):59-66.
27. Friesen DT, Shanker R, Crew M, Smithey DT, Curatolo WJ, Nightingale JAS. 2008. Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: An overview. Mol Pharm 5(6):1003-1019.
28. Simonelli AP, Mehta SC, Higuchi WI. 1970. Inhibition of sulfathiazole crystal growth by polyvinylpyrrolidone. J Pharm Sci 59:633-638.
29. Ziller KH, Rupprecht H. 1988. Control of crystal growth in drug suspension. Drug Dev Ind Pharm 14:2341-2370.
30. Davis AF, Hadgraft J. 1991. Effect of supersaturation on membrane transport: I. Hydrocortisone acetate. Int J Pharm 76:1-8.
31. Lipp R. 1998. Selection and use of crystallization inhibitors for matrix-type transdermal drug-delivery systems containing sex steroids. J Pharm Pharmacol 50:1343-1349.
32. Usai F, Maeda K, Kusai A, Nishimura K, Yamamoto K. 1997. Inhibitory effects of water-soluble polymers on the precipitation of RS-8359. Int J Pharm 154:59-66.